Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol add-on therapy in treatment-refractory first-episode psychosis
2013-000240-26Phase 2Terminated
- Sponsor
- King's College London
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of cannabidiol in schizophrenia and Schizophrenia Spectrum Disorders (SSD), sponsored by King's College London. Primary endpoints: PANSS score, GAF score and 3 more. Started Oct 2013; status: terminated.
02
Drugs
cannabidiol
03
Conditions
schizophreniaSchizophrenia Spectrum Disorders (SSD)
Beyond the preview
Go deeper on 2013-000240-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000240-26.